Biomedical Engineering Reference
In-Depth Information
7. Newton R, Hart L, Chung KF, Barnes PJ. Ceramide induction of COX-2 and
PGE
2
in pulmonary A549 cells does not involve activation of NF-
k
B.
Biochem Biophys Res Commun 2000; 277:675-679.
8. Pavord ID, Tattersfield AE. Bronchoprotective role for endogenous prosta-
glandin E
2
. Lancet 1995; 344:436-438.
9. Meja KK, Barnes PJ, Giembycz MA. Characterization of the prostanoid
receptor(s) on human blood monocytes at which prostaglandin E
3
inhibits
lipopolysaccharide-induced tumour necrosis factor-a. Br J Pharmacol 1997;
122:149-157.
10. Spicuzza L, Giembycz MA, Barnes PJ, Belvisi MG. Prostaglandin E
2
suppres-
sion of acetylcholine release from parasympathetic nerves innervating guinea-
pig trachea by interacting with prostanoid receptors of the EP3-subtype. Br J
Pharmacol 1998; 123:1246-1252.
11. Au BT, Teixeira MM, Collins PD, Williams TJ. Effect of PDE4 inhibitors on
zymosan-induced IL-8 release from human neutrophils: synergism with pros-
tanoids and salbutamol. Br J Pharmacol 1998; 123:1260-1266.
12. Borchers MT, Carty MP, Leikauf GD. Regulation of human airway mucins
by acrolein and inflammatory mediators. Am J Physiol 1999; 276:L549-L555.
13. Stone R, Barnes PJ, Fuller RW. Contrasting effects of prostaglandins E2 and
F2 alpha on sensitivity of the human cough reflex. J Appl Physiol 1992;
73:649-653.
14. Lee LY, Kwong K, Lin YS, Gu Q. Hypersensitivity of bronchopulmonary
C-fibers induced by airway mucosal inflammation: cellular mechanisms. Pulm
Pharmacol Ther 2002; 15:199-204.
15. Tamaoki J, Chiyotani A, Kobayashi S, Noritaka T, Kanemura T, Takizawa
T. Effect of indomethacin on bronchorrhea with chronic bronchitis, diffuse
panbronchiolitis or bronchiectasis. Am Rev Respir Dis l992; 145:548-552.
16. Nichol G, Nix A, Barnes PJ, Chung KF. Prostaglandin F
2a
enhancement of
capsaicin induced cough in man: modulation by beta
2
-adrenergic and anticho-
linergic drugs. Thorax 1990; 45:694-698.
17. Shamsuddin M, Chen E, Anderson J, Smith LJ. Regulation of leukotriene and
platelet-activating factor synthesis in human alveolar macrophages. J Lab Clin
Med 1997; 130:615-626.
18. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and
8-isoprostane in exhaled breath condensate of patients with exacerbations of
COPD. Thorax 2003; 58:294-298.
19. Hill AT, Bayley D, Stockley RA. The interrelationship of sputum inflamma-
tory markers in patients with chronic bronchitis. Am J Respir Crit Care
Med 1999; 160:893-898.
20. Been KM, Kornmann O, Buhl R, Culpitt SV, Giembycz MA, Barnes PJ.
Neutrophil chemotactic activity of sputum from patients with COPD: role
of interleukin 8 and leukotriene B
4
. Chest 2003; 123:1240-1247.
21. Seggev JS, Thornton WH Jr, Edes TE. Serum leukotriene B
4
levels in patients
with obstructive pulmonary disease. Chest 1991; 99:289-291.
22. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene
B
4
receptor BLT2. A new therapeutic target in inflammation and immunolo-
gical disorders. J Exp Med 2000; 192:421-432.
